04/08/2023 List of Related Persons of the Company in the Semi-Annual Corporate Governance Report 2023, No. 858/BC-DBD dated July 29, 2023
25/07/2023 Explanation for the Variance of 10% or More in Net Profit After Tax on the Consolidated and Separate Financial Statements for the Second Quarter of 2023 Compared to the Same Period in 2022
17/07/2023 Resolution of the Board of Directors No. 814/NQ-HĐQT dated July 17, 2023 on the Selection of the Auditing Firm for 2023
30/06/2023 Resolution of the Board of Directors No. 736/NQ-DBD-HĐQT dated June 30, 2023 on the Implementation of the Investment in a Small-Volume Parenteral Drug Manufacturing Plant
06/05/2023 Corporate Governance Regulations of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar) – 2023
28/04/2023 Explanation for the Variance of 10% or More in Net Profit After Tax on the Consolidated and Separate Financial Statements for the First Quarter of 2023 Compared to the Same Period in 2022
10/04/2023 List of Candidates for Election to the Board of Directors: Mr. Nguyễn Ngọc Dũng, Mr. Trương Thanh Liêm
31/03/2023 Letter of Resignation from the Position of Chairman of the Board of Directors by Mr. Nguyễn Văn Quá
31/03/2023 Decision of the Board of Directors on the Dismissal of Mr. Nguyễn Văn Quá from the Position of Chairman of the Board of Directors
31/03/2023 Decision of the Board of Directors on the Election of Mr. Nguyễn Tiến Hải as Chairman of the Board of Directors
28/03/2023 Explanation for the Variance of 10% or More in Net Profit After Tax on the Consolidated and Separate Financial Statements for 2022 Compared to the Same Period of the Previous Year
30/01/2023 Explanation for the variance of 10% or more in net profit after tax on the separate financial statements for the fourth quarter of 2022 compared to the same period of the previous year
30/01/2023 Explanation for the variance of 10% or more in net profit after tax on the consolidated financial statements for the fourth quarter of 2022 compared to the same period of the previous year
26/10/2022 Explanation of the difference of 10% or more in NPAT of the 3rd quarter consolidated financial statements of the third quarter of 2022 compared to the same period last year
